Report ID |
45370 |
Drug Identification Number |
01927620 |
Brand name |
MYOCHRYSINE |
Common or Proper name |
MYOCHRYSINE 10MG/ML LJ AMP5 |
Company Name |
SANOFI-AVENTIS CANADA INC |
Market Status |
CANCELLED POST MARKET |
Active Ingredient(s) |
GOLD SODIUM THIOMALATE |
Strength(s) |
10MG |
Dosage form(s) |
SOLUTION |
Route of administration |
INTRAMUSCULAR |
Packaging size |
5 AMPOULES |
ATC code |
M01CB |
ATC description |
SPECIFIC ANTIRHEUMATIC AGENTS |
Reason for shortage |
Other (Please describe in comments) |
Anticipated start date |
2018-04-04 |
Actual start date |
2018-04-04 |
Estimated end date |
2019-09-30 |
Actual end date |
2019-06-04 |
Shortage status |
Resolved |
Updated date |
2019-06-10 |
Company comments |
The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally. |
Health Canada comments |
|
Tier 3 Status |
No |
Company contact information |
email: CAINTERNET@sanofi.com
Telephone: 1-800-265-7927 |